Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)

Stopped early · Phase 2/Phase 3

Conditions studied: Cystic Fibrosis Related Diabetes

In brief

This is a study to find out if Levemir® (a long acting or basal insulin) is safe and effective in treating cystic fibrosis related diabetes (CFRD).

Key facts

Study ID

NCT00639626

Run by

Nationwide Children's Hospital

People needed

6

Starts

2008-08-01

Expected to finish

2010-05-01

Last updated by the study team

2018-04-12

Who can join

Age: 16 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with CFRD by oral glucose tolerance test (OGTT) who are medically stable. Medical stability will be defined as:
• No hospital admission for six weeks or more before the study
• No oral or intravenous antibiotics for at least six weeks preceding the study (subjects will be allowed to use low doses of inhaled corticosteroids).

You may not qualify if…

• Use of oral or intravenous corticosteroid medications within six weeks of the study.
• Evidence of clinically significant liver disease.
• Colonization with Burkholderia cepacia.
• Colonization with Aspergillus.
• Pregnancy.
• Medically unstable (stability defined above).

Where it is running

• Nationwide Children's Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.